![]() ![]() The Medical Letter on Drugs and Therapeutics concluded in 2001 that oxycodone offered no advantage over appropriate doses of other potent opioids. ![]() ![]() Ox圜ontin's commercial success did not depend on the merits of the drug compared with other available opioid preparations. However, fundamental changes in the promotion and marketing of controlled drugs by the pharmaceutical industry, and an enhanced capacity of the FDA to regulate and monitor such promotion, can positively affect public health. Under current regulations, the Food and Drug Administration (FDA) is limited in its oversight of the marketing and promotion of controlled drugs. 1 The high availability of Ox圜ontin correlated with increased abuse, diversion, and addiction, and by 2004 Ox圜ontin had become a leading drug of abuse in the United States. Sales grew from $48 million in 1996 to almost $1.1 billion in 2000. When Purdue Pharma introduced Ox圜ontin in 1996, it was aggressively marketed and highly promoted. An in-depth analysis of the promotion and marketing of Ox圜ontin (Purdue Pharma, Stamford, CT), a sustained-release oxycodone preparation, illustrates some of the key issues. CONTROLLED DRUGS, WITH their potential for abuse and diversion, can pose public health risks that are different from-and more problematic than-those of uncontrolled drugs when they are overpromoted and highly prescribed. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |